NASDAQ : RGEN
Repligen Corporation — Key statistics
Healthcare · Medical Instruments & Supplies · United States
Last price 176.94 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 11.31B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 11.06B |
| Enterprise Value | 10.88B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 63.92M |
| Shares Outstanding | 63.92M |
| Shares Change (YoY) | +0.43% |
| Shares Change (QoQ) | -0.14% |
| Owned by Insiders (%) | 0.28% |
| Owned by Institutions (%) | 109.83% |
| Float | 60.96M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 70.79 |
| PS Ratio | 13.72 |
| Forward PS | 10.78 |
| PB Ratio | 4.69 |
| P/TBV Ratio | 16.11 |
| P/FCF Ratio | 103.60 |
| P/OCF Ratio | 85.13 |
| PEG Ratio | 2.91 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 13.51 |
| EV / EBITDA | 75.85 |
| EV / EBIT | 165.93 |
| EV / FCF | 102.00 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.88 |
| Quick Ratio | 8.07 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 3.55 |
| Debt / FCF | 6.49 |
| Interest Coverage | 2.72 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -0.57% |
| Return on Assets (ROA) | 1.40% |
| Return on Invested Capital (ROIC) | -4.81% |
| Return on Capital Employed (ROCE) | 2.34% |
| Weighted Average Cost of Capital (WACC) | 9.28% |
| Revenue Per Employee | $402,805 |
| Profits Per Employee | -$5,902 |
| Employee Count | 2,000 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 2.17 |
Taxes
| Measure | Value |
|---|
| Income Tax | 20.03M |
| Effective Tax Rate | 243.43% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.08 |
| 52-Week Price Change | +16.03% |
| 50-Day Moving Average | 177.89 |
| 200-Day Moving Average | 144.82 |
| Relative Strength Index (RSI) | 45.77 |
| Average Volume (20 Days) | 1,455,124 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.15M |
| Short Previous Month | 7.58M |
| Short % of Shares Out | 11.18% |
| Short % of Float | 11.72% |
| Short Ratio (days to cover) | 5.48 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 805.61M |
| Gross Profit | 433.14M |
| Operating Income | 65.60M |
| Pretax Income | 8.23M |
| Net Income | -11.80M |
| EBITDA | 143.50M |
| EBIT | 65.60M |
| Loss Per Share | -$0.21 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 862.98M |
| Total Debt | 692.24M |
| Net Cash | 170.74M |
| Net Cash Per Share | $2.67 |
| Equity (Book Value) | 2.09B |
| Book Value Per Share | 36.90 |
| Working Capital | 1.12B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 129.86M |
| Capital Expenditures | -23.15M |
| Depreciation & Amortization | 77.90M |
| Net Borrowing | n/a |
| Free Cash Flow | 106.72M |
| FCF Per Share | $1.67 |
Margins
| Measure | Value |
|---|
| Gross Margin | 53.77% |
| Operating Margin | 8.14% |
| Pretax Margin | 1.02% |
| Profit Margin | -1.47% |
| EBITDA Margin | 17.81% |
| EBIT Margin | 8.14% |
| FCF Margin | 13.25% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.43% |
| Shareholder Yield | -0.43% |
| Earnings Yield | -0.12% |
| FCF Yield | 0.97% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $203.45 |
| Price Target Difference | 17.64% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (3Y) | 18.95% |
| EPS Growth Forecast (3Y) | 26.32% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 6.92 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |